Chronic rejection of major histocompatibility complex class II-disparate skin grafts after anti-CD3 therapy: a model of antibody-independent transplant vasculopathy

Transplantation. 1998 Dec 15;66(11):1537-44. doi: 10.1097/00007890-199812150-00019.

Abstract

Background: Chronic rejection remains a leading cause of allograft loss. Histologically, it is characterized by arterial intimal thickening and parenchymal fibrosis. The immune mechanisms triggering chronic rejection are still uncompletely understood.

Methods: We performed major histocompatibility complex (MHC) class H-incompatible skin grafts from C-H2bm12 (bm12, H2bm12) into C57BL/6 (C57BL/6, H2b) recipients immunosuppressed with a short course of anti-CD3 monoclonal antibodies to prevent acute rejection.

Results: More than 80% of grafts survived for prolonged periods, but eventually all displayed macroscopic and microscopic evidence of chronic rejection. At histology, there was a progressive arterial intimal thickening as well as intense dermal fibrosis. This was accompanied by an inflammatory infiltrate consisting of lymphocytes and macrophages, but also of a considerable number of eosinophils. Mice with chronic rejection were unable to generate anti-donor MHC class II cytotoxic T lymphocyte activity at either 20 or 60 days after transplant. Furthermore, transplantation of bm12 skins on C57BL/6-congenic, Ig knock-out mice was associated with the development of a chronic rejection that was identical to that occurring in wild-type C57BL/6 animals, indicating that alloantibodies are not necessary in this model.

Conclusions: (1) Skin grafts may undergo chronic rejection with the characteristic lesions of vasculopathy and fibrosis; (2) chronic rejection of MHC class II-disparate skins may occur in the absence of direct cytotoxic T lymphocyte activity or alloantibodies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / therapeutic use
  • CD3 Complex / immunology*
  • Chronic Disease
  • Female
  • Graft Rejection / therapy
  • Histocompatibility Antigens Class II / analysis*
  • Immunoglobulins / deficiency
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Skin Transplantation / adverse effects
  • Skin Transplantation / immunology*
  • T-Lymphocytes, Cytotoxic / physiology
  • Vascular Diseases / etiology

Substances

  • Antibodies
  • CD3 Complex
  • Histocompatibility Antigens Class II
  • Immunoglobulins